menu search
Trades24h logo
 Register
close Tap here to search
  1. Home

  2. News

  3. Stock Details

Subscribe To  

  Price Alert   Latest News   Economic Calendar News

KZIA / Kazia Therapeutics expands further in North America with Toronto glioblastoma study

Kazia Therapeutics expands further in North America with Toronto glioblastoma study
Kazia Therapeutics Ltd (ASX:KZA, NASDAQ:KZIA)'s cancer drug, paxalisib, which targets glioblastoma, will now reach patients in Canada through a new study at Sunnybrook Health Sciences Centre in Toronto, Ontario. The company's flagship drug, paxalisib, is a candidate in GBM AGILE, a multi-drug platform study designed to identify promising new therapies for glioblastoma. Read More
Hmarkets Logo
Demo chevron_right Live Account chevron_right See Partner Details

Content Topics

Silvercrest

Metals

Inc

Silv

Therapeutics

Expands

Further

America

Toronto

Glioblastoma

Stock

KZIA

Posted: Nov 28 2021, 21:12
Author Name: Proactive Investors
Views: 102146

KZIA News  

KAZIA TO PRESENT FINAL DATA FROM PAXALISIB PHASE II STUDY IN GLIOBLASTOMA AT ESMO

By PRNewsWire
September 8, 2022

KAZIA TO PRESENT FINAL DATA FROM PAXALISIB PHASE II STUDY IN GLIOBLASTOMA AT ESMO

SYDNEY , Sept. 8, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, today announ more_horizontal

Kazia Therapeutics appoints US-based CFO to assist global market expansion

By Proactive Investors
December 12, 2021

Kazia Therapeutics appoints US-based CFO to assist global market expansion

Kazia Therapeutics Ltd (ASX:KZA, NASDAQ:KZIA) has appointed Karen Krumeich as chief financial officer to focus on building and maintaining relationsh more_horizontal

Kazia Therapeutics appoints US-based CFO to assist global market expansion

By Proactive Investors
December 12, 2021

Kazia Therapeutics appoints US-based CFO to assist global market expansion

Kazia Therapeutics Ltd (ASX:KZA, NASDAQ:KZIA) has appointed Karen Krumeich as chief financial officer to focus on building and maintaining relationsh more_horizontal

Kazia Therapeutics appoints US-based CFO to assist global market expansion

By Proactive Investors
December 12, 2021

Kazia Therapeutics appoints US-based CFO to assist global market expansion

Kazia Therapeutics Ltd (ASX:KZA, NASDAQ:KZIA) has appointed Karen Krumeich as chief financial officer to focus on building and maintaining relationsh more_horizontal

Kazia Therapeutics expands further in North America with Toronto glioblastoma study

By Proactive Investors
November 28, 2021

Kazia Therapeutics expands further in North America with Toronto glioblastoma study

Kazia Therapeutics Ltd (ASX:KZA, NASDAQ:KZIA)'s cancer drug, paxalisib, which targets glioblastoma, will now reach patients in Canada through a new more_horizontal

Kazia Therapeutics expands further in North America with Toronto glioblastoma study

By Proactive Investors
November 28, 2021

Kazia Therapeutics expands further in North America with Toronto glioblastoma study

Kazia Therapeutics Ltd (ASX:KZA, NASDAQ:KZIA)'s cancer drug, paxalisib, which targets glioblastoma, will now reach patients in Canada through a new more_horizontal

Kazia Therapeutics expands further in North America with Toronto glioblastoma study

By Proactive Investors
November 28, 2021

Kazia Therapeutics expands further in North America with Toronto glioblastoma study

Kazia Therapeutics Ltd (ASX:KZA, NASDAQ:KZIA)'s cancer drug, paxalisib, which targets glioblastoma, will now reach patients in Canada through a new more_horizontal

Kazia Therapeutics appoints former Cellectar Biosciences chief medical officer John Friend as new CMO

By Proactive Investors
November 14, 2021

Kazia Therapeutics appoints former Cellectar Biosciences chief medical officer John Friend as new CMO

Kazia Therapeutics Ltd (ASX:KZA, NASDAQ:KZIA) has appointed John Friend MD, the former chief medical officer (CMO) at Cellectar Biosciences (NASDAQ:CL more_horizontal

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

©2014-2024 All Rights Reserved. I.C

Hand-crafted & made with Love

logo close

Search within

Pages Search Results: